Kopans Receives the Kushner Writing Award

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

BETHESDA, Md--Daniel B. Kopans, MD, of the Department of Radiology, Massachusetts General Hospital and Harvard Medical School, has received the 1996 Rose Kushner Award for Writing Achievement in the Field of Breast Cancer for best scientific article.

BETHESDA, Md--Daniel B. Kopans, MD, of the Department of Radiology,Massachusetts General Hospital and Harvard Medical School, hasreceived the 1996 Rose Kushner Award for Writing Achievement inthe Field of Breast Cancer for best scientific article.

His contribution, Mammography screening and the controversy concerningwomen aged 40 to 49, appeared in Radiologic Clinics of North America.

Other winners of the Kushner awards, sponsored by the AmericanMedical Writers Association and Zeneca Pharmaceuticals, were HeidiRosvold-Brenholtz for best lay article (Breast health, NationalWomen's Health Report) and Robin Y. Wood, EdD, for best script(Breast health for women over 60, HealthWood, Inc.).

Also, Diane Robertson-Steele for best brochure or monograph (High-dosechemotherapy with bone marrow transplant for metastatic breastcancer, ECRI) and Rita Baron-Faust for best book (Breast Cancer:What Every Woman Should Know (Hearst/William Morrow &Co.).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content